Krishna Institute of Medical Sciences Limited has informed the Exchange regarding Board meeting held on August 06, 2025.
KIMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts more than Nifty Smallcap 250 and 0.8 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Krishna Institute of Medical Sciences Limited (KIMS) announced its Q1 FY26 results after a board meeting on August 6, 2025. Consolidated revenue from operations grew 26.6% YoY to ₹8,716 million from ₹6,884 million in Q1 FY25. However, consolidated profit after tax declined about 10.7% to ₹850 million from ₹952 million, and EPS fell to ₹1.96 from ₹2.16. Standalone revenue grew about 14% YoY to ₹3,734 million while standalone PAT dipped to ₹588 million from ₹607 million. Total expenses grew faster than revenue (around 35% YoY at consolidated level), driven by higher employee costs, finance costs, and other expenses, which squeezed margins. The statutory auditor, S.R. Batliboi & Associates LLP, issued an unmodified (clean) review opinion on both sets of results. Four subsidiaries reported an aggregate net loss of ₹138 million, partially weighing on consolidated earnings.
Strong top-line growth signals healthy business expansion across KIMS hospital network, but the sharp rise in operating and finance costs has compressed profitability, which may temper near-term investor enthusiasm. Watch for margin trends in coming quarters to see if the cost pressure is temporary (expansion-related) or structural.